L M R B Arantes1, A C de Carvalho2, M E Melendez2, C C Centrone3, J F Góis-Filho4, T N Toporcov5, D N Caly6, E H Tajara7, E M Goloni-Bertollo7, A L Carvalho8. 1. Department of Molecular Biology, São José do Rio Preto Medical School (FAMERP), São José do Rio Preto, SP, Brazil; Molecular Oncology Research Center, Barretos Cancer Hospital - Pio XII, Barretos, SP, Brazil. 2. Molecular Oncology Research Center, Barretos Cancer Hospital - Pio XII, Barretos, SP, Brazil. 3. Virology Laboratory, Institute of Tropical Medicine of São Paulo, University of São Paulo, São Paulo, SP, Brazil. 4. Head and Neck Surgery Service, Arnaldo Vieira de Carvalho Cancer Institute (ICAVC), São Paulo, SP, Brazil. 5. Faculty of Public Health, University of São Paulo (FSP), São Paulo, SP, Brazil. 6. Laboratory of Clinical Pathology, Heliópolis Hospital, São Paulo, SP, Brazil. 7. Department of Molecular Biology, São José do Rio Preto Medical School (FAMERP), São José do Rio Preto, SP, Brazil. 8. Molecular Oncology Research Center, Barretos Cancer Hospital - Pio XII, Barretos, SP, Brazil. Electronic address: alopescarvalho@uol.com.br.
Abstract
PURPOSE: Activation of proto-oncogenes and inactivation of tumour suppressor genes are the major genetic alterations involved in carcinogenesis. The increase in methylation at the promoter region of a tumour suppressor gene can lead to gene inactivation, selecting cells with proliferative advantage. Thus, promoter hypermethylation is considered a marker in a variety of malignant tumours, including oral cavity. EXPERIMENTAL DESIGN: The methylation pattern of eight genes was evaluated in 40 oral cavity squamous cell carcinomas (OSCCs) and 40 saliva samples from healthy individuals by Q-MSP. Different combinations of genes were also assessed in order to identify gene panels that could better distinguish between OSCC and saliva samples. RESULTS: CCNA1, DAPK, DCC and TIMP3 methylation were highly specific for being found in the OSCC samples. Moreover, the combination of these genes improved detection when compared with single markers, reaching values of 92.5% for sensitivity and specificity (when using the panel CCNA1, DCC, TIMP3). Moreover, DAPK, DCC and TIMP3 were hypermethylated in nearly 90% of clinically T1 and T2 cases. CONCLUSION: The pursuing of this panel of hypermethylated genes is an important tool for the detection of individuals with OSCC. Moreover, the identification of these markers in early stages of OSCC shows the feasibility of using the panel on saliva as possible biomarkers for early diagnosis. The lack of association between the methylation status of these genes and clinical characteristics shows that they are able to distinguish OSCC cases irrespective of social and clinical factors (gender, age, human papillomavirus (HPV) status, clinical stage, vascular embolisation and perineural invasion).
PURPOSE: Activation of proto-oncogenes and inactivation of tumour suppressor genes are the major genetic alterations involved in carcinogenesis. The increase in methylation at the promoter region of a tumour suppressor gene can lead to gene inactivation, selecting cells with proliferative advantage. Thus, promoter hypermethylation is considered a marker in a variety of malignant tumours, including oral cavity. EXPERIMENTAL DESIGN: The methylation pattern of eight genes was evaluated in 40 oral cavity squamous cell carcinomas (OSCCs) and 40 saliva samples from healthy individuals by Q-MSP. Different combinations of genes were also assessed in order to identify gene panels that could better distinguish between OSCC and saliva samples. RESULTS:CCNA1, DAPK, DCC and TIMP3 methylation were highly specific for being found in the OSCC samples. Moreover, the combination of these genes improved detection when compared with single markers, reaching values of 92.5% for sensitivity and specificity (when using the panel CCNA1, DCC, TIMP3). Moreover, DAPK, DCC and TIMP3 were hypermethylated in nearly 90% of clinically T1 and T2 cases. CONCLUSION: The pursuing of this panel of hypermethylated genes is an important tool for the detection of individuals with OSCC. Moreover, the identification of these markers in early stages of OSCC shows the feasibility of using the panel on saliva as possible biomarkers for early diagnosis. The lack of association between the methylation status of these genes and clinical characteristics shows that they are able to distinguish OSCC cases irrespective of social and clinical factors (gender, age, human papillomavirus (HPV) status, clinical stage, vascular embolisation and perineural invasion).
Authors: Megan A Clarke; Patricia Luhn; Julia C Gage; Clara Bodelon; S Terence Dunn; Joan Walker; Rosemary Zuna; Stephen Hewitt; J Keith Killian; Liying Yan; Andrew Miller; Mark Schiffman; Nicolas Wentzensen Journal: Int J Cancer Date: 2017-05-26 Impact factor: 7.396
Authors: Ilda Patrícia Ribeiro; Francisco Caramelo; Francisco Marques; Ana Domingues; Margarida Mesquita; Leonor Barroso; Hugo Prazeres; Maria José Julião; Isabel Poiares Baptista; Artur Ferreira; Joana Barbosa Melo; Isabel Marques Carreira Journal: Cell Oncol (Dordr) Date: 2016-08-04 Impact factor: 6.730
Authors: Helen R Moinova; Thomas LaFramboise; James D Lutterbaugh; Apoorva Krishna Chandar; John Dumot; Ashley Faulx; Wendy Brock; Omar De la Cruz Cabrera; Kishore Guda; Jill S Barnholtz-Sloan; Prasad G Iyer; Marcia I Canto; Jean S Wang; Nicholas J Shaheen; Prashanti N Thota; Joseph E Willis; Amitabh Chak; Sanford D Markowitz Journal: Sci Transl Med Date: 2018-01-17 Impact factor: 19.319
Authors: Cláudia Maria Pereira; Ana Carolina de Carvalho; Felipe Rodrigues da Silva; Matias Eliseo Melendez; Roberta Cardim Lessa; Valéria Cristina C Andrade; Luiz Paulo Kowalski; André L Vettore; André Lopes Carvalho Journal: BMC Cancer Date: 2018-02-17 Impact factor: 4.430